The US-Israeli company Oramed is currently testing a corona vaccine that can be swallowed. Here you can find out what this so-called oral vaccination is all about and what advantages it promises.
Roll up your sleeves, expose your upper arm and give a little spade – this is how the corona vaccination works . That could change soon. The US-Israeli company Oramed wants to bring a corona vaccine onto the market that is easy and uncomplicated to swallow in tablet form.
Table of Contents
Corona vaccine to swallow: Easier distribution
Oramed boss Nadav Kidron spoke in an interview with the Jerusalem Post about the new oral vaccination and its advantages. “An oral COVID-19 vaccine would remove several barriers to rapid, large-scale spread and allow people to take the vaccine themselves at home.”
According to Kidron, the drug is a yeast-based vaccine that requires less time and money to produce compared to the previously approved vaccines. The vaccine can also be shipped at refrigerator temperature and even stored at room temperature, “making it logistically easier to distribute anywhere in the world,” Kidron said. Even if the corona vaccination has to be refreshed annually like the flu vaccination , the oral vaccine could become even more valuable.
Corona oral vaccination not yet approved
The new vaccine targets three structural proteins of the coronavirus. In comparison, Moderna and Pfizer’s vaccines only target a single spike protein. The new vaccine to be swallowed would have another decisive advantage. He is more resistant to the Covid mutations, according to Kidron. Since oral medication tends to have fewer side effects , this could also apply to oral vaccinations, according to the Oramed boss.
It will be a while before the oral vaccination is approved. The vaccine is currently in the first phase of clinical trials. This means that it has only been tested on animals and not yet on humans. There he is said to have already demonstrated that he stimulates the formation of important antibodies that protect against viral infection. In the second quarter of the year, the new vaccine will also be tested on humans.
